Has Daniel Lovell received payments from drug or device companies?

Yes. Drug and device makers reported $91,707 in general payments to Daniel Lovell across 138 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Lovell did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Lovell come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Lovell

Pediatric Rheumatology · Cincinnati, OHNPI 1568482719

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $66,108 of the $91,707 with a category attached, or 72.1%. 15 manufacturers reported payments, led by Pfizer at 50.0% of the total. Reporting peaked in 2019 at $35,056 and has fallen 99.5% since, to $177 in 2025. Among pediatric rheumatology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$91,707in general payments, 2019–2025

Across 138 payments — averaging $664.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$46K
AbbVie$20K
Genentech USA, Inc.$7K
E.r. Squibb & Sons, L.L.C.$5K
Eli Lilly$4K
Novartis Pharma AG$3K
plus $7K from 9 others

$312,661in research payments, 2019–2025

Across 89 payments — averaging $3513.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$123K
Roche Products Limited$85K
Genentech, Inc.$74K
Pfizer$21K
E.r. Squibb & Sons, L.L.C.$7K
F. Hoffmann-la Roche AG$1K
plus $218 from 1 others

What the payments were for

Consulting fees$66,10872%
Speaking & faculty fees$20,48322%
Travel & lodging$2,9393%
Food & beverage$1,5752%
Education$6011%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	46	$45,875
AbbVie(2 entities)	27	$20,229
Genentech USA, Inc.	7	$6,668
E.r. Squibb & Sons, L.L.C.	7	$4,599
Eli Lilly	3	$3,938
Novartis Pharma AG	1	$3,368
Janssen Research & Development, LLC	2	$2,590
Novartis	21	$2,033
Azurity Pharmaceuticals, Inc.	1	$1,250
AstraZeneca	1	$450
F. Hoffmann-la Roche AG	2	$333
Amgen	16	$304
GSK	2	$26
Fresenius Kabi USA, LLC	1	$26
Lightforce Orthodontics, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XELJANZ$41,551
Actemra$6,899
Rinvoq$4,303
COSENTYX$3,368
SIMPONI$1,350
Xatmep$1,250
ILARIS$118
Tavneos$110

How this compares

$91,707 in reported general payments places this provider in the 95th percentile of 35 pediatric rheumatology providers in Ohio.

See all pediatric rheumatology providers in Ohio →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TavneosAvacopan	11	$182,735
Orencia ClickjectAbatacept	13	$69,298
Leflunomide	11	$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenTavneos	$304	$182,73511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 pediatric rheumatology providers in Ohio.

Other pediatric rheumatology in Cincinnati

Hermine BrunnerCincinnati$531K
Alexei GromCincinnati$63K
Grant SchulertCincinnati$45K
Tracy TingCincinnati$2K
Michael MattCincinnati$1K
Michael HenricksonCincinnati$764
Esi MorganCincinnati$750
Jennifer HugginsCincinnati$609
McKenzie VaterCincinnati$579
Ivanna RomankevychCincinnati$576

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →